Eiger BioPharmaceuticals, Inc.
EIGR
Rang in aandelen
#36453
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Aandeelprijs
$1.73
Laatst gesynchroniseerd: 2025-06-17
Marktkapitalisatie
$2.55M
Verandering (1 dag)
-0.29%
Verandering (1 jaar)
-79.71%
Land
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)
Categorie
Healthcare
Winst voor Eiger BioPharmaceuticals, Inc. (EIGR)
Winst in Dec 2023 TTM: $-74.96M
Volgens de meest recente financiële verslagen van Eiger BioPharmaceuticals, Inc. bedraagt de huidige winst van het bedrijf $-74.96M. In 2022 behaalde het bedrijf een winst van $-96.75M, een daling ten opzichte van de winst van 2021, die $-33.85M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Eiger BioPharmaceuticals, Inc. van 2016 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-74.96M | 0.00% |
| 2023 | $-74.96M | -22.53% |
| 2022 | $-96.75M | 185.80% |
| 2021 | $-33.85M | -47.96% |
| 2020 | $-65.05M | -7.40% |
| 2019 | $-70.25M | 34.09% |
| 2018 | $-52.39M | 23.42% |
| 2017 | $-42.45M | -9.85% |
| 2016 | $-47.09M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | -7,137.23% |
US
|
|
| $-3.09B | 4,018.36% |
US
|
|
| $-4.02B | 5,258.00% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,702.36% |
NL
|
